F S&P 500
5,119.25 +37.00 (+0.73%) F Dow Jones
38,324.00 +36.00 (+0.09%) F Nasdaq
17,743.75 +176.25 (+1.00%) E-mini Russell 2000 Index Futur
1,993.10 -0.10 (-0.01%) Petróleo
84.11 +0.54 (+0.65%) Oro
2,355.50 +13.00 (+0.55%)
PepGen Inc. (PEPG)
Fuera de horario:
PepGen Inc.
321 Harrison Avenue
8th Floor
Boston, MA 02118
United States
781 797 0979
https://pepgen.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 64
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. James G. McArthur Ph.D. | President, CEO, Treasurer, Secretary & Director | 834.98k | N/D | 1962 |
| Mr. Noel P. Donnelly M.B.A. | Chief Financial Officer | 650.17k | N/D | 1970 |
| Mr. Niels Svenstrup Ph.D. | Senior Vice President of Chemistry, Manufacturing & Control | 455.15k | N/D | 1970 |
| Dr. Michael Gait Ph.D. | Founder & Scientific Advisory Board Member | N/D | N/D | N/D |
| Ms. Mary Beth DeLena | General Counsel & Secretary | N/D | N/D | N/D |
| Dr. Michelle L. Mellion M.D. | Senior VP & Head of Clinical Development | N/D | N/D | 1976 |
| Ms. Emiko Bryant | Chief of Staff | N/D | N/D | N/D |
| Mr. Kyle Breidenstine | VP of Finance & Controller | N/D | N/D | N/D |
Descripción
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients. The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is based in Boston, Massachusetts.
Gestión corporativa
La calificación ISS Governance QuickScore de PepGen Inc. a partir del 1 de abril de 2024 es 8. Las puntuaciones principales son Auditoría: 7; Junta: 6; Derechos del accionista: 8; Compensación: 9.
